Is it time for clinical trials of invasive group A and groups C and G Streptococcus infections?

Ravindra Dotel^{a b}✉, Asha C Bowen^{c d}, Ouli Xie^{e f}, Katherine B. Gibney^{e g}, Jonathan Rhys Carapetis^{c d}, Joshua Saul Davis^h, Steven Y. C. Tong^{e g}

1. ^aDepartment of Infectious Diseases, Blacktown Hospital, Sydney, Australia. Electronic address: r_dotel@yahoo.com
2. ^bDepartment of Infectious Diseases, Blacktown Hospital, Sydney, Australia
3. ^cDepartment of Infectious Diseases, Perth Children's Hospital, Perth, Australia
4. ^dWesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia
5. ^eDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
6. ^fMonash Infectious Diseases, Monash Health, Melbourne, Australia
7. ^gVictorian Infectious Diseases Service, The Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
8. ^hSchool of Medicine and Public Health, University of Newcastle, New South Wales, Australia
9. ✉Corresponding author